Cargando…
The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3‐isopropylpyrazolyl)borate (Tp(iPr)), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed includ...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064950/ https://www.ncbi.nlm.nih.gov/pubmed/31560142 http://dx.doi.org/10.1002/chem.201903605 |
_version_ | 1783504966588039168 |
---|---|
author | Berasaluce, Iker Cseh, Klaudia Roller, Alexander Hejl, Michaela Heffeter, Petra Berger, Walter Jakupec, Michael A. Kandioller, Wolfgang Malarek, Michael S. Keppler, Bernhard K. |
author_facet | Berasaluce, Iker Cseh, Klaudia Roller, Alexander Hejl, Michaela Heffeter, Petra Berger, Walter Jakupec, Michael A. Kandioller, Wolfgang Malarek, Michael S. Keppler, Bernhard K. |
author_sort | Berasaluce, Iker |
collection | PubMed |
description | The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3‐isopropylpyrazolyl)borate (Tp(iPr)), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed include (O,O‐) (S,O‐) (N,N‐) donors that have been successfully coordinated to the molybdenum center by means of oxygen‐atom transfer (OAT) reactions from the known Mo(VI) starting material, Tp(iPr)MoO(2)Cl. The synthesized complexes were characterized by standard analytical methods and where possible by X‐ray diffraction analysis. The aqueous stability of the compounds was studied by means of UV/Vis spectroscopy and the impact of the attached ligand scaffolds on the oxidation potentials (Mo(IV) to Mo(V)) was studied by cyclic voltammetry. Utilizing polyvinylpyrrolidone (PVP) as a solubilizing agent, adequate aqueous solubility for biological tests was obtained. Anticancer activity tests and preliminary mode of action studies have been performed in vitro and in vivo. |
format | Online Article Text |
id | pubmed-7064950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70649502020-03-16 The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects Berasaluce, Iker Cseh, Klaudia Roller, Alexander Hejl, Michaela Heffeter, Petra Berger, Walter Jakupec, Michael A. Kandioller, Wolfgang Malarek, Michael S. Keppler, Bernhard K. Chemistry Full Papers The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3‐isopropylpyrazolyl)borate (Tp(iPr)), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed include (O,O‐) (S,O‐) (N,N‐) donors that have been successfully coordinated to the molybdenum center by means of oxygen‐atom transfer (OAT) reactions from the known Mo(VI) starting material, Tp(iPr)MoO(2)Cl. The synthesized complexes were characterized by standard analytical methods and where possible by X‐ray diffraction analysis. The aqueous stability of the compounds was studied by means of UV/Vis spectroscopy and the impact of the attached ligand scaffolds on the oxidation potentials (Mo(IV) to Mo(V)) was studied by cyclic voltammetry. Utilizing polyvinylpyrrolidone (PVP) as a solubilizing agent, adequate aqueous solubility for biological tests was obtained. Anticancer activity tests and preliminary mode of action studies have been performed in vitro and in vivo. John Wiley and Sons Inc. 2019-11-19 2020-02-17 /pmc/articles/PMC7064950/ /pubmed/31560142 http://dx.doi.org/10.1002/chem.201903605 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Full Papers Berasaluce, Iker Cseh, Klaudia Roller, Alexander Hejl, Michaela Heffeter, Petra Berger, Walter Jakupec, Michael A. Kandioller, Wolfgang Malarek, Michael S. Keppler, Bernhard K. The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects |
title | The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects |
title_full | The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects |
title_fullStr | The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects |
title_full_unstemmed | The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects |
title_short | The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects |
title_sort | first anticancer tris(pyrazolyl)borate molybdenum(iv) complexes: tested in vitro and in vivo—a comparison of o,o‐, s,o‐, and n,n‐chelate effects |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064950/ https://www.ncbi.nlm.nih.gov/pubmed/31560142 http://dx.doi.org/10.1002/chem.201903605 |
work_keys_str_mv | AT berasaluceiker thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT csehklaudia thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT rolleralexander thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT hejlmichaela thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT heffeterpetra thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT bergerwalter thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT jakupecmichaela thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT kandiollerwolfgang thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT malarekmichaels thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT kepplerbernhardk thefirstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT berasaluceiker firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT csehklaudia firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT rolleralexander firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT hejlmichaela firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT heffeterpetra firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT bergerwalter firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT jakupecmichaela firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT kandiollerwolfgang firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT malarekmichaels firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects AT kepplerbernhardk firstanticancertrispyrazolylboratemolybdenumivcomplexestestedinvitroandinvivoacomparisonofoosoandnnchelateeffects |